Amarin Corp Plc (AMRN)

[Biobillionair]

JL
Of special importance is a recent decision from the federal courts that says the FDA can not prevent a drug from listing benefits unless the FDA can prove that the information is false or misleading..At present time there is no impediment to AMRN advertising Vascepa (EPA) has been shown to lower insulin resistance in diabetics (the crucial thing)..or that EPA has been shown to improve CVD event outcomes in certain types of lipid abnormalities, and that EPA lowers inflammatory markers and this suggests it might be effective in atherosclerosis..

If my red neck legal degree read this correctly, Amarin could use AACE guidelines as a Marketing Tool.

Anyway to get a statement from Physicians urging the FDA not to end surrogate markers for drug development in the DM 2 population? It would cover lipid and new DM 2 blood sugar drugs recently approved or in process.